This brand name is authorized in Ecuador, Tunisia, South Africa
The drug SUPLASYN contains one active pharmaceutical ingredient (API):
|
1
Hyaluronate sodium
UNII YSE9PPT4TH - HYALURONATE SODIUM
|
|
|
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| SUPLASYN Solution for injection | Web Search | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| D03AX05 | Hyaluronic acid | D Dermatologicals → D03 Preparations for treatment of wounds and ulcers → D03A Cicatrizants → D03AX Other cicatrizants |
| S01KA01 | Hyaluronic acid | S Sensory organs → S01 Ophthalmologicals → S01K Surgical aids → S01KA Viscoelastic substances |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 6431-MEE-0721, 6432-MEE-0721 |
| Country: TN | Direction de la Pharmacie et du Médicament | Identifier(s): 10783011 |
| Country: ZA | Health Products Regulatory Authority | Identifier(s): A39/3.2/0352 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
